Q-omics provides the consensus-scored PPM1K-DT profile across patient tissues and cancer cell-line models. PPM1K-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, PPM1K-DT is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PPM1K-DT RNA expression shows 8,745 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight CHOL, KIRC, and PAAD as cancer lineages where PPM1K-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1K-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1K-DT survival associations across molecular data types. PPM1K-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1K-DT RNA expression–survival associations across cancer types. High PPM1K-DT expression shows unfavorable associations in LAML and COAD, but favorable associations in CHOL, ESCA, CESC and LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for PPM1K-DT RNA expression.
This table summarizes PPM1K-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPM1K-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1K-DT shows lower tumor expression in KIRC, HNSC, KIRP, KICH, UCEC and LUSC. The KIRC box plot shows higher PPM1K-DT RNA expression in normal versus tumor tissue (log2 FC = −0.583, t-test p < 0.001).
This table shows molecular features associated with PPM1K-DT in patient tissues and cancer cell lines. In patient samples, PPM1K-DT shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
